

Large-scale cancer cell line screening

Advance your lead compound to validated candidate through large-scale cancer cell line screening. OmniScreen provides key tumor killing activity data early in the drug development process to progress your anticancer agents with confidence.



OmniScreen regular screening benefits include:

- Cost-effectiveness through optimized operational efficiency and waived cell line revival fee.
- Time saving thanks to a rapidly scalable cell line bank, allowing you to make informed decisions early in your drug discovery process.
- Clean results with high quality cell lines, fully verified by STR analysis and mycoplasma contamination free.
- Consistent study design with well-established and controlled 96 or 384-well assay formats, amenable to assessing a range of agents including kinase inhibitors, epigenetic modulators, small and large molecules.
- Flexibility in model choice of 60 or more cancer cell lines from an extensive collection of over 500 models.
- Simplified target-driven model selection with XenoBase®, our online database collating genomic, transcriptomic, and pharmacological response data.
- Reliable results with comparison treatment data available for quality control.
- Extensive experience in combination assays and screens, including proprietary CrownSyn™ drug combination analysis service.
- Additional support from our experienced bioinformatics team to assist you with novel target and biomarker of response identification.
- Seamless transition from *in vitro* to *in vivo* studies with matched cell line derived xenograft models.

Choose from four unique subpanels of cell lines:

- **OmniPanel™**: a growing collection of more than 450 cancer cell lines.
- **XenoSelect™**: over 170 cancer cell lines with corresponding xenograft models to rapidly move to *in vivo* studies.
- **RNAseq panel**: over 190 cell lines with in-house RNAseq data for target identification.
- **PrimePanel™**: a growing collection of over 30 primary cancer cells derived from PDX models for improved clinical relevance.

Cell-Based Compound Screening



Bioinformatics Analysis

Novel Target & Hypothesis

Biomarkers of Response

In Vitro Validation Panel

In Vivo Validation



Contact Sales

US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com



Schedule Scientific Consultation

Request a consultation to discuss your project.
consultation@crownbio.com



Explore Scientific Data

Log into XenoBase to review cell line data.
xenobase.crownbio.com